Clinical efficacy of entecavir in the treatment of hepatitis B cirrhosis complicated with hepatic diabetes
10.3969/j.issn.1005-1678.2017.10.090
- VernacularTitle:恩替卡韦治疗乙型肝炎肝硬化伴肝源性糖尿病的临床应用效果
- Author:
jiao Chun CHEN
1
;
Jing ZHOU
Author Information
1. 浙江省永康市第一人民医院 感染科
- Keywords:
hepatitis B cirrhosis;
hepatic diabetes;
entecavir;
Cave;
insulin resistance;
islet cell function;
application effect
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(10):213-214
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical efficacy of entecavir in the treatment of hepatitis B cirrhosis associated with hepatic diabetes. Methods 78 cases of hepatitis B Hepatic Cirrhosis with diabetes were selectedfrom June 2015 to December 2016, and randomly divided into study group (n=39) and control group (n=39). The study group were treated with entecavir, the control group were treated with adefovir dipivoxil. Two groups of patients with hepatitis B cirrhosis combined with hepatic diabetes were treated continuously for 48 weeks, the changes of FPG, HOMA-β, beta and HOMA-IR were recorded. Results There was no significant difference between the two groups in the treatment of FPG, HOMA-β, and HOMA-IR. After treatment, the two groups of FPG and HOMA-IR decreased significantly compared with before treatment, while HOMA-β was significantly higher than before treatment, but the changes of the above indexes in the study group were better than those in the control group (P<0.05). Conclusion Entecavir combined with hypoglycemic agents can achieve more ideal blood glucose control effect in patients with hepatitis B cirrhosis combined with hepatic diabetes..
